Beyond Objective Responses: Amivantamab Demonstrates Significant Clinical Benefit in Recurrent Adenoid Cystic Carcinoma
Posted innews Oncology Otorhinolaryngology

Beyond Objective Responses: Amivantamab Demonstrates Significant Clinical Benefit in Recurrent Adenoid Cystic Carcinoma

A Phase 2 clinical trial of amivantamab, an EGFR-MET bispecific antibody, in recurrent or metastatic adenoid cystic carcinoma (ACC) showed a 72.2% clinical benefit rate. While the primary objective response rate was low, the high rate of disease stabilization highlights its potential in managing this rare malignancy.
Intensity-Modulated Proton Therapy Reduces Acute Toxicity While Maintaining Oncologic Equivalence in Nasopharyngeal Carcinoma: A Five-Year Case-Control Analysis
Posted innews Oncology Otorhinolaryngology

Intensity-Modulated Proton Therapy Reduces Acute Toxicity While Maintaining Oncologic Equivalence in Nasopharyngeal Carcinoma: A Five-Year Case-Control Analysis

A case-control study comparing IMPT and IMRT for nasopharyngeal carcinoma shows that IMPT significantly reduces grade 2+ acute toxicities without compromising long-term survival or local-regional control, suggesting a superior therapeutic index during the acute treatment phase.
Beyond the Binary: A New 4-Stage Stratification System Revolutionizes Cochlear Implant Candidacy Assessment
Posted innews Otorhinolaryngology

Beyond the Binary: A New 4-Stage Stratification System Revolutionizes Cochlear Implant Candidacy Assessment

Researchers have developed a 4-level classification system using routine audiometric data to estimate cochlear implant candidacy likelihood. This tool moves beyond traditional binary screening, providing a probability gradient that enhances shared decision-making and may improve utilization rates for eligible adults.
Proton Therapy Outperforms Photons in Oropharyngeal Cancer: Superior Survival and Reduced Toxicity in a Phase 3 Trial
Posted innews Oncology Otorhinolaryngology

Proton Therapy Outperforms Photons in Oropharyngeal Cancer: Superior Survival and Reduced Toxicity in a Phase 3 Trial

A landmark Phase 3 trial establishes Intensity-Modulated Proton Therapy (IMPT) as a new standard for oropharyngeal cancer, demonstrating non-inferior progression-free survival, significantly improved overall survival, and a marked reduction in long-term toxicities such as gastrostomy tube dependence.